Having driven generic utilization about as far as possible, plan sponsors are turning to a method of controlling drug costs that had all but disappeared. Aggressive contracting is driving this trend, but that may soon yield to evidence-based evaluation.
Paul E. Terry, PhD
Don Liss, MD
Advanced therapy management may lead to physician acceptance of additional medications infused at home
This study verifies, as defined by current guidelines, that initial treatment with fixed dose combinations (FDC) is associated with a better likelihood of HbA1c goal attainment and lower health care resource use and costs.
Though ROI is hard to calculate, insurer says that its on-site clinics are changing employee behavior for the good
A tiny new implantable heart pump transmits speed, power consumption, and blood flow data directly to the cardiac center